Computer-Based identification of a novel LIMK1/2 inhibitor that synergizes with salirasib to destabilize the actin cytoskeleton

Oncotarget

Volumn 3, Issue 6, 2012, Pages 629-639

  Mashiach Farkash, Efrat ^a   Rak, Roni ^a   Elad Sfadia, Galit ^a   Haklai, Roni ^a   Carmeli, Shmuel ^a   Kloog, Yoel ^a   Wolfson, Haim J ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cofilin; Limk; Rac; Ras; Rho

Indexed keywords

ANTINEOPLASTIC AGENT; COFILIN; EPHRIN A3; LIM KINASE 1; LIM KINASE 2; NEUROFIBROMIN; P21 ACTIVATED KINASE 1; PROTEIN SERINE THREONINE KINASE; RAC1 PROTEIN; SALIRASIB; T56 LIM KINASE INHIBITOR; UNCLASSIFIED DRUG;

ACTIN FILAMENT; ANIMAL CELL; ARTICLE; BINDING SITE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL MOTILITY; CELL PROLIFERATION; COLONY FORMATION; COMPUTER ANALYSIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DISEASE ASSOCIATION; DRUG EFFECT; DRUG POTENTIATION; EMBRYO; ENZYME ACTIVE SITE; ENZYME SUBSTRATE COMPLEX; FIBROBLAST; MIGRATION INHIBITION; MOLECULAR MODEL; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION;

EID: 84868612402     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.525     Document Type: Article

References (38)

1. Pollard TD, Borisy GG. Cellular motility driven by assembly and disassembly of actin filaments. Cell. 2003; 112:453-465.
2. Ozawa T, Araki N, Yunoue S, Tokuo H, Feng L, Patrakitkomjorn S, Hara T, Ichikawa Y, Matsumoto K, Fujii K, Saya H. The neurofibromatosis type 1 gene product neurofibromin enhances cell motility by regulating actin filament dynamics via the Rho-ROCK-LIMK2-cofilin pathway. J Biol Chem. 2005; 280:39524-39533.
3. Manetti F, Brullo C, Magnani M, Mosci F, Chelli B, Crespan E, Schenone S, Naldini A, Bruno O, Trincavelli ML, Maga G, Carraro F, Martini C, Bondavalli F, Botta M. Structure-based optimization of pyrazolo[3,4-d]pyrimidines as Abl inhibitors and antiproliferative agents toward human leukemia cell lines. J Med Chem. 2008; 51:1252-1259.
4. Arber S, Barbayannis FA, Hanser H, Schneider C, Stanyon CA, Bernard O, Caroni P. Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase. Nature. 1998; 393:805-809.
5. Yang N, Higuchi O, Ohashi K, Nagata K, Wada A, Kangawa K, Nishida E, Mizuno K. Cofilin phosphorylation by LIM-kinase 1 and its role in Rac-mediated actin reorganization. Nature. 1998; 393:809-812.
6. Wang W, Mouneimne G, Sidani M, Wyckoff J, Chen X, Makris A, Goswami S, Bresnick AR, Condeelis JS. The activity status of cofilin is directly related to invasion, intravasation, and metastasis of mammary tumors. J Cell Biol. 2006; 173:395-404.
7. Van Troys M, Huyck L, Leyman S, Dhaese S, Vandekerkhove J, Ampe C. Ins and outs of ADF/cofilin activity and regulation. Eur J Cell Biol. 2008; 87:649-667.
8. Wang W, Eddy R, Condeelis J. The cofilin pathway in breast cancer invasion and metastasis. Nat Rev Cancer. 2007; 7:429-440.
9. Donnai D, Karmiloff-Smith A. Williams syndrome: from genotype through to the cognitive phenotype. Am J Med Genet. 2000; 97:164-171.
10. Kelly ML, Chernoff J. Getting smart about p21-activated kinases. Mol Cell Biol. 2011; 31:386-387.
11. Starinsky-Elbaz S, Faigenbloom L, Friedman E, Stein R, Kloog Y. The pre-GAP-related domain of neurofibromin regulates cell migration through the LIM kinase/cofilin pathway. Mol Cell Neurosci. 2009; 42:278-287.
12. Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM, Saulino AM, Fountain JW, Brereton A, Nicholson J, Mitchell AL. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science. 1990; 249:181-186.
13. Marchuk DA, Saulino AM, Tavakkol R, Swaroop M, Wallace MR, Andersen LB, Mitchell AL, Gutmann DH, Boguski M, Collins FS. cDNA cloning of the type 1 neurofibromatosis gene: complete sequence of the NF1 gene product. Genomics. 1991; 11:931-940.
14. Buchberg AM, Cleveland LS, Jenkins NA, Copeland NG. Sequence homology shared by neurofibromatosis type-1 gene and IRA-1 and IRA-2 negative regulators of the RAS cyclic AMP pathway. Nature. 1990; 347:291-294.
15. Cichowski K, Jacks T. NF1 tumor suppressor gene function: narrowing the GAP. Cell. 2001; 104:593-604.
16. Barkan B, Starinsky S, Friedman E, Stein R, Kloog Y. The Ras inhibitor farnesylthiosalicylic acid as a potential therapy for neurofibromatosis type 1. Clin Cancer Res. 2006; 12:5533-5542.
17. Manetti F. LIM kinases are attractive targets with many macromolecular partners and only a few small molecule regulators. Med Res Rev. 2011.
18. Barkan B, Kloog Y, Ehrlich M. Phenotypic Reversion of Invasive Neurofibromin-Deficient Schwannoma by FTS: Ras Inhibition Reduces BMP4/Erk/Smad Signaling. Mol Cancer Ther. 2011; 8:1317-1326.
19. Fahsold R, Hoffmeyer S, Mischung C, Gille C, Ehlers C, Kucukceylan N, Abdel-Nour M, Gewies A, Peters H, Kaufmann D, Buske A, Tinschert S, Nurnberg P. Minor lesion mutational spectrum of the entire NF1 gene does not explain its high mutability but points to a functional domain upstream of the GAP-related domain. Am J Hum Genet. 2000; 66:790-818.
20. Katz E, Sims AH, Sproul D, Caldwell H, Dixon JM, Meehan RR, Harrison DJ: Targeting of Rac GTPases blocks the spread of intact human breast cancer. Oncotarget. 2012; in press.
21. Ong C, Jubb A, Zhou W, Haverty P, Harris A, Belvin M, Friedman L, Koeppen H, Hoeflich K: p21-activated kinase 1: PAK'ed with potential. Oncotarget. 2011; 2:491-496.
22. Nagata K, Ohashi K, Yang N, Mizuno K. The N-terminal LIM domain negatively regulates the kinase activity of LIM-kinase 1. Biochem J. 1999; 343 Pt 1:99-105.
23. Kadrmas JL, Beckerle MC. The LIM domain: from the cytoskeleton to the nucleus. Nat Rev Mol Cell Biol. 2004; 5:920-931.
24. Ross-Macdonald P, de Silva H, Guo Q, Xiao H, Hung CY, Penhallow B, Markwalder J, He L, Attar RM, Lin TA, Seitz S, Tilford C, Wardwell-Swanson J, Jackson D. Identification of a nonkinase target mediating cytotoxicity of novel kinase inhibitors. Mol Cancer Ther. 2008; 7:3490-3498.
25. Wrobelski ST LS, Leftheris K, He L, Seitz SP, Lin T-A, Vaccaro W Phenyl-substituted pyrimidine compounds useful as kinase inhibitors. In. Edited by WO, vol. 084017 A2; 2006.
26. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ. Basic local alignment search tool. J Mol Biol. 1990; 215:403-410.
27. Roy A, Kucukural A, Zhang Y. I-TASSER: a unified platform for automated protein structure and function prediction. Nat Protoc. 2010; 5:725-738.
28. Eswar N, Webb B, Marti-Renom MA, Madhusudhan MS, Eramian D, Shen MY, Pieper U, Sali A. Comparative protein structure modeling using MODELLER. Curr Protoc Protein Sci. 2007; Chapter 2:Unit 2 9.
29. Huang D, Zhou T, Lafleur K, Nevado C, Caflisch A. Kinase selectivity potential for inhibitors targeting the ATP binding site: a network analysis. Bioinformatics. 2010; 26:198-204.
30. Irwin JJ, Shoichet BK. ZINC-a free database of commercially available compounds for virtual screening. J Chem Inf Model. 2005; 45:177-182.
31. Zhao L, Au JL, Wientjes MG. Comparison of methods for evaluating drug-drug interaction. Front Biosci (Elite Ed). 2010; 2:241-249.
32. Raftopoulou M, Hall A. Cell migration: Rho GTPases lead the way. Dev Biol. 2004; 265:23-32. 33.
33. Etienne-Manneville S. In vitro assay of primary astrocyte migration as a tool to study Rho GTPase function in cell polarization. Methods Enzymol. 2006; 406:565-578.
34. Goldberg L, Kloog Y. A Ras Inhibitor Tilts the Balance between Rac and Rho and Blocks PI3-Kinase-Dependent Glioblastoma Cell Migration. Cancer Res. 2006; 66:11709-11717.
35. Weber GL, Parat MO, Binder ZA, Gallia GL, Riggins GJ. Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget. 2011; 2:833-849.
36. Haklai R, Gana-Weisz G, Elad G, Paz A, Marciano D, Egozi Y, Ben Baruch G, Kloog Y. Dislodgment and accelerated degradation of Ras. Biochemistry. 1998; 37:1306-1314.
37. Gana-Weisz M, Halaschek-Wiener J, Jansen B, Elad G, Haklai R, Kloog Y. The Ras inhibitor S-trans, transfarnesylthiosalicylic acid chemosensitizes human tumor cells without causing resistance. Clin Cancer Res. 2002; 8:555-565.
38. Shapira S, Barkan B, Fridman E, Kloog Y, Stein R. The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways. Cell Death Differ. 2007; 5:895-906.